Despite limited evidence on its effectiveness in children, T-20 (enfuvirtide, Fuzeon) has been approved for use in children aged six years or older at a dose of 2mg/kg twice daily, up to a maximum of 90mg twice daily. This dose results in similar drug levels to the adult dose, and is unaffected by age, weight or developmental stage^[1]. The safety of T-20 in children and infants below six years of age is yet to be established.

Preliminary research has found that mild to moderate injection site reactions are common amongst children. Fever and wheezing were also reported^[2].